New pill aims to boost power of standard myeloma treatment
NCT ID NCT07082270
Summary
This early-stage trial is testing a new oral drug called selvigaltin (GB1211) when added to a standard three-drug combination for multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find the safest dose and understand the side effects of this four-drug combination in about 21 patients. Researchers hope blocking a specific protein (galectin-3) with the new pill may make the standard treatment more effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.